Immune evasion mediated by PD-L1 on glioblastoma-derived extracellular vesicles
Open accessThe DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Abstract
. These results suggest that PD-L1 on EVs may be another mechanism for glioblastoma to suppress antitumor immunity and support the potential of EVs as biomarkers in tumor patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“EVs derived from a variety of tumor types including melanoma, glioblastoma, breast, and head and neck cancer contain functional PD-L1 on their surface (Chen et al., 2018; Ricklefs et al., 2018; Theodoraki et al., 2018).”
From Hallmarks of response, resistance, and toxicity to immune checkpoint blockade (2021) · cites this paper as Ricklefs et al., 2018
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Radiotherapy Plus Concomitant and Adjuvant Temozolomide for Glioblastoma
Stupp, R., Mason, W. P., van den Bent, M. J., Weller, M., Fisher, B., Taphoorn, M. J. B., Belanger, K., Brandes, A. A., Marosi, C., Bogdahn, U., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043330 · Cited by 21,807
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
Comprehensive genomic characterization defines human glioblastoma genes and core pathways
The Cancer Genome Atlas Research Network (2008) · Nature · doi:10.1038/nature07385 · Cited by 7,735
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
Motzer, R. J., Escudier, B., McDermott, D. F., George, S., Hammers, H. J., Srinivas, S., Tykodi, S. S., Sosman, J. A., Procopio, G., Plimack, E. R., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1510665 · Cited by 5,807
Causal analysis approaches in Ingenuity Pathway Analysis
Krämer, A., Green, J., Pollard, J., & Tugendreich, S. (2014) · Bioinformatics · doi:10.1093/bioinformatics/btt703 · Cited by 5,724
Freeman, G. J., Long, A. J., Iwai, Y., Bourque, K., Chernova, T., Nishimura, H., Fitz, L. J., Malenkovich, N., Okazaki, T., Byrne, M. C., et al. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.7.1027 · Cited by 5,294 · cited 1×
“One of themost prominent molecules used by tumor cells to engage T cell immune checkpoints is programmed death ligand 1 (PD-L1) (9, 10).”
BackgroundSelf-citationSingle-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma
Patel, A. P., Tirosh, I., Trombetta, J. J., Shalek, A. K., Gillespie, S. M., Wakimoto, H., Cahill, D. P., Nahed, B. V., Curry, W. T., Martuza, R. L., et al. (2014) · Science · doi:10.1126/science.1254257 · Cited by 5,063
Cited by
Items 401–500 of 632
Mechanical regulation of extracellular vesicle activity during tumour progression
Parihar, K., Liu, D.-A., Hassan, G., Issadore, D., Janmey, P. A., Weaver, V. M., Guo, W., & Radhakrishnan, R. (2025) · Nature Biomedical Engineering · doi:10.1038/s41551-025-01446-0 · Cited by 14
Recent advances in immunotherapy for gliomas: overcoming barriers and advancing precision strategies
Jabri, A., Mhannayeh, A., Taftafa, B., Alsharif, M., Sibai, D., Alsharif, R., Abbad, T., Elsalti, A., Ahmed, Z., Salma, J., et al. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1690464 · Cited by 13
“Once taken up by other immune cells, these EVs can reprogram them into more suppressive, less effective states (30).”
Himes, B. T., Fain, C. E., Tritz, Z. P., Nesvick, C. L., Jin‐Lee, H. J., Geiger, P. A., Peterson, T. E., Jung, M.-Y., & Parney, I. F. (2022) · Journal of neurosurgery · doi:10.3171/2022.6.jns2274 · Cited by 11
Microglial Extracellular Vesicles as Modulators of Brain Microenvironment in Glioma
Catalano, M., Serpe, C., & Limatola, C. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232113165 · Cited by 12
“GBM-derived EVs suppress the activation of T lymphocytes, partially through the programmed death ligand-1 (PD-L1) [80], a key player of the tumor immune escape in many”
BackgroundInfluentialThe role of extracellular vesicles in immune cell exhaustion and resistance to immunotherapy
Aghakhani, A., Pezeshki, P. S., & Rezaei, N. (2024) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2024.2360209 · Cited by 11
“The presence of several immune checkpoints such as PD-L1 on the surface of TDEVs has been demonstrated to weaken the efficacy of ICI in various cancer types such as melanoma [85–88], glioblastoma [89], breast cancer [90], and chronic lymphocytic leukemia (CLL) [91].”
EV Translational Horizons as Viewed Across the Complex Landscape of Liquid Biopsies
Killingsworth, B., Welsh, J. A., & Jones, J. C. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.556837 · Cited by 11
Chen, Z.-K., Zheng, S., Long, Y., Wang, K.-M., Xiao, B.-L., Li, J.-B., Zhang, W., Song, H., & Chen, G. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.08.027 · Cited by 10
Tuning a Bioengineered Hydrogel for Studying Astrocyte Reactivity in Glioblastoma
DePalma, T. J., Hisey, C. L., Hughes, K., Fraas, D., Tawfik, M., Scharenberg, J., Wiggins, S., Nguyen, K. T., Hansford, D. J., Reátegui, E., et al. (2024) · Acta Biomaterialia · doi:10.1016/j.actbio.2024.09.048 · Cited by 10
Extracellular Vesicle-Based Strategies for Tumor Immunotherapy
Jiramonai, L., Liang, X.-J., & Zhu, M. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17020257 · Cited by 9
“EVs containing PD-L1 potentially cause the induction of an immunosuppressive cytokine, IL-10 [131].”
Liu, M., Wang, Y., Chen, X., Zeng, Y., Huang, W., Yang, J., Dai, H., Cheng, L., Mauro, C., & Cheung, K. C.-P. (2025) · Clinical Epigenetics · doi:10.1186/s13148-025-01900-5 · Cited by 10
Ren, X., Wu, J., Li, J., Zhai, Z., Li, X., Guan, F., Wang, M., Ma, X., Tan, Z., Kang, H., et al. (2025) · Experimental Hematology and Oncology · doi:10.1186/s40164-025-00693-w · Cited by 12
“Pretreatment of glioblastoma EVs with anti-PD-1 antibody significantly reversed the inhibition of T cells and prevented tumor progression [56].”
Accurate and rapid quantification of PD-L1 positive exosomes by a triple-helix molecular probe
Fan, Z., Weng, Q., Li, Y., Zeng, T., Wang, J., Zhang, H., Yu, H. T., Dong, Y., Zhao, X., & Li, J. (2023) · Analytica Chimica Acta · doi:10.1016/j.aca.2023.340984 · Cited by 10
Abscopal Effect, Extracellular Vesicles and Their Immunotherapeutic Potential in Cancer Treatment
Salazar, A., Chavarria, V., Flores, I., Ruiz, S., de la Cruz, V. P., Sánchez‐García, F. J., & Pineda, B. (2023) · Molecules · doi:10.3390/molecules28093816 · Cited by 11
“It has been reported that in several types of cancer the expression of these molecules is directly correlated with the later stages of the disease [99,100].”
BackgroundLi, Y., Yang, Q., Li, D., Li, W., & Men, W. (2025) · International Journal of Nanomedicine · doi:10.2147/ijn.s502363 · Cited by 10
“29 With the advancement of research, the role of exosome PD-L1 in facilitating immune evasion is gradually elucidated, and associated molecules are being unveiled one by one.”
Prominosomes - a particular class of extracellular vesicles containing prominin-1/CD133?
Karbanová, J., Thamm, K., Fargeas, C. A., Deniz, I. A., Lorico, A., & Corbeil, D. (2025) · Journal of Nanobiotechnology · doi:10.1186/s12951-025-03102-w · Cited by 11
“Cancer cell-derived EVs may stimulate neo-angiogenesis at the primary cancer site [28–30] and modulate immune responses [31–33].”
Extracellular Vesicles in Cancer Progression: Are They Part of The Problem or Part of The Solution?
Scholl, J. N., Dias, C. K., Müller, L., Battastini, A. M. O., & Figueiró, F. (2020) · Nanomedicine · doi:10.2217/nnm-2020-0256 · Cited by 12
Noronha, C., Ribeiro, A. S., Taipa, R. J. F., Leitão, D., Schmitt, F. C., Reis, J., Faria, C. C., & Paredes, J. (2022) · Journal of Neuro-Oncology · doi:10.1007/s11060-021-03907-3 · Cited by 10
Tumour Derived Extracellular Vesicles: Challenging Target to Blunt Tumour Immune Evasion
Lopatina, T., Sarcinella, A., & Brizzi, M. F. (2022) · Cancers · doi:10.3390/cancers14164020 · Cited by 11
Polymers in Engineering Extracellular Vesicle Mimetics: Current Status and Prospective
Wei, X., Liu, S., Cao, Y., Wang, Z., & Chen, S. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15051496 · Cited by 10
Santos, N. L., Bustos, S. O., Bhatt, D., Chammas, R. J., & Andrade, L. N. D. S. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.737449 · Cited by 11
Consensus statement on microglial and macrophage functions in gliomas
Zheng, Y., Alzoubi, I., Graeber, M. B., Anand, A., Barazzuol, L., Dorostkar, M. M., Frontzek, K., Golebiewska, A., Hadjipanayis, C. G., Hortobágyi, T., et al. (2026) · Acta Neuropathologica · doi:10.1007/s00401-026-02999-3 · Cited by 15
Self-citationDevelopment of In Vitro Assays for Advancing Radioimmunotherapy against Brain Tumors
Walter, Y. A., Hubbard, A., Benoit, A., Jank, E., Salas, O., Jordan, D., & Ekpenyong, A. E. (2022) · Biomedicines · doi:10.3390/biomedicines10081796 · Cited by 9
Unraveling the peripheral and local role of inflammatory cytokines in glioblastoma survival
Cavalheiro, V. J., Campos, A. C. P., de Lima, L. G. C. A., Roça, C. T., Docema, M. F. L., Lancellotti, C. L. P., Martinez, R. C. R., Pagano, R. L., Chammas, R. J., Teixeira, M. J., et al. (2022) · Cytokine · doi:10.1016/j.cyto.2022.156059 · Cited by 9
Donati, G., D’Amore, V. M., Russomanno, P., Cerofolini, L., Amato, J., Marzano, S., Salobehaj, M., Rizzo, D., Assoni, G., Carotenuto, A., et al. (2023) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2023.06.006 · Cited by 9
Challenges and perspectives for immunotherapy in oesophageal cancer: A look to the future (Review)
Lampis, A., Ratti, M., Ghidini, M., Mirchev, M. B., Okuducu, A. F., Valeri, N., & Hahne, J. C. (2021) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2021.4930 · Cited by 9
Wang, P., Liang, Z., Li, W., Li, Z., & Ma, Q. (2025) · Analytical Chemistry · doi:10.1021/acs.analchem.4c06670 · Cited by 8
Exosome-based immunotherapy in hepatocellular carcinoma
Liu, Z., Wang, G., Li, Z., Zhang, W., Zhang, W., Zhang, X., Liu, F., & Gao, J. (2025) · Clinical and Experimental Medicine · doi:10.1007/s10238-025-01659-2 · Cited by 9
“In the experimental glioblastoma models, exosomal PD-L1 secreted by TEXs suppressed the proliferation of both CD4 + and CD8 + T cells and reduced the expression of CD69 and CD25, which function as essential markers of T cell activation [47].”
Extracellular membrane particles en route to the nucleus – exploring the VOR complex
Lorico, A., Santos, M. F., Karbanová, J., & Corbeil, D. (2025) · Biochemical Society Transactions · doi:10.1042/bst20253005 · Cited by 9
Pang, C., & Wang, Y. (2025) · Immunology · doi:10.1111/imm.70087 · Cited by 11
Zhou, S., Zhang, X., Lin, J., Fenfen, M., Chen, H., CHEN, J., & Luan, X. (2026) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2026.01.015 · Cited by 10
Zhao, Y., Lyu, X., Wu, X., Liu, Y., Zhang, N., Wei, W., & Liu, M. (2026) · Journal of Clinical Investigation · doi:10.1172/jci194715 · Cited by 8
“…surveillance through multiple mechanisms, such as (a) activating cytosolic surveillance sensors (150, 151, 187), (b) modulating immune checkpoints (179, 180, 188), (c) regulating NK/T cell cytotoxicity (152, 156), and (d) influencing macrophage and DC phagocytic clearance (171, 172, 175, 176).”
CD27+ microparticle interactions and immunoregulation of CD4+ T lymphocytes
Cagnet, L., Neyrinck-Leglantier, D., Tamagne, M., Berradhia, L., Khelfa, M., Cléophax, S., Pirenne, F., & Vingert, B. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1043255 · Cited by 9
Masood, A. B., Batool, S., Bhatti, S. N., Ali, A., Valko, M., Jomová, K., & Kuča, K. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1202098 · Cited by 8
“Extracellular vesicles that promote the progression of GBM are also shown to express PD-L1 on their surface and therefore are considered to participate in immunosuppression (11).”
BackgroundPiro, A., Cufaro, M. C., Lanuti, P., Brocco, D., Lellis, L. D., Florio, R., Pilato, S., Pagotto, S., Fabritiis, S. D., Vespa, S., et al. (2024) · Cancers · doi:10.3390/cancers16101795 · Cited by 8
“Considering that this experimental condition may reflect the physiological conditions where T lymphocytes can interact with costimulatory cells [21], we analyzed the effect of PC-derived EVs in this context.”
BackgroundExtracellular vesicles in cancer: golden goose or Trojan horse
Han, T., Hao, Q., Chao, T., Sun, Q., Chen, Y., Gao, B., Guan, L., Ren, W., & Zhou, X. Y. (2024) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjae025 · Cited by 10
“…can directly activate PD-1/PD-L1 immune checkpoint, thus impairing the proliferation of CD8 + T cells, inhibiting interleukin 2 (IL-2) and interferon gamma (IFN γ ) production, and increasing overall tumor burden (Chen et al., 2018 ; Ricklefs et al., 2018 ; Kim et al., 2019 ; Daassi et al., 2020 ).”
BackgroundShedding Light on the Role of Exosomal PD-L1 (ExoPD-L1) in Cancer Progression: an Update
Sun, D., Altalbawy, F. M. A., Yumashev, A. V., Hjazi, A. M., Menon, S. V., Kaur, M., Deorari, M., Abdulwahid, A. S., Shakir, M. N., & Gabal, B. C. (2024) · Cell Biochemistry and Biophysics · doi:10.1007/s12013-024-01340-7 · Cited by 8
“Furthermore, EVs secreted by glioblastoma stem-like cells (GSCs) exhibit surface expression of PD-L1 and are instrumental in directing the blocking of anti-CD3 mAb-mediated induction and proliferation of both CD4 + and CD8 + T cells [74].”
Walker, S. N., Lucas, K., Dewey, M. J., Badylak, S. F., Hussey, G. S., Flax, J. D., & McGrath, J. L. (2024) · Small · doi:10.1002/smll.202405505 · Cited by 13
Nie, L., Ma, J., Yu, Y., Tao, Y., Song, Z., & Li, J. (2024) · Biochemical Pharmacology · doi:10.1016/j.bcp.2024.116699 · Cited by 11
Regulatory T Cell Mimicry by a Subset of Mesenchymal GBM Stem Cells Suppresses CD4 and CD8 Cells
Johnson, A. L., Khela, H. S., Korleski, J., Sall, S., Li, Y., Zhou, W., Smith-Connor, K., Lopez-Bertoni, H., & Laterra, J. (2025) · Cells · doi:10.3390/cells14080592 · Cited by 9
Small extracellular vesicles as a multicomponent biomarker platform in urinary tract carcinomas
Szeliski, K., Drewa, T. A., & Pokrywczyńska, M. (2022) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2022.916666 · Cited by 8
“Different studies have shown that different cancer-derived EVs may carry higher levels of immunosuppressive molecules such as macrophage migration inhibitory factor or PD-L1 forming metastatic niche (Costa-Silva et al., 2015; Chen et al., 2018; Ricklefs et al., 2018).”
BackgroundQuantitative imaging of vesicle–protein interactions reveals close cooperation among proteins
Cha, M., Jeong, S. H., Jung, J.-H., Baeg, Y., Park, S., Bae, S., Lim, C. S., Park, J. H., Lee, J., Gho, Y. S., et al. (2023) · Journal of Extracellular Vesicles · doi:10.1002/jev2.12322 · Cited by 8
Anti‐PD ‐1 treatment protects against seizure by suppressing sodium channel function
Yang, Y., Chen, Z., Zhou, J., Jiang, S., Wang, G., Wan, L., Yu, J., Jiang, M., Wang, Y., Hu, J., et al. (2023) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.14504 · Cited by 9
Decoding vesicle-based precision oncology in gliomas
Batool, S., Hsia, T., Khanna, S. K., Gamblin, A. S., Rosenfeld, Y. B., You, D., Carter, B. S., & Balaj, L. (2022) · Neuro-Oncology Advances · doi:10.1093/noajnl/vdac035 · Cited by 7
Self-citationHu, S., Chen, G., Luo, A., Zhao, H., Li, D., Peng, B., Du, J., & Luo, D. (2025) · Biology Direct · doi:10.1186/s13062-025-00651-w · Cited by 7
“PD-L1 in glioblastoma-derived-EVs markedly suppress T cell activation [28].”
Shpigelman, J., & Rao, K. (2025) · Immunology · doi:10.1111/imm.70033 · Cited by 9
Zhao, Y., Zhang, D., Meng, L., Shan, S., Zhang, C., Deng, Z., Han, C., & Kong, L. (2025) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2025.10.030 · Cited by 7
Translating Molecular Insights into Effective Targeting of Glioblastoma Stem Cells
Singh, S., Kapkoti, D. S., & Singh, G. (2026) · Cancers · doi:10.3390/cancers18050860 · Cited by 8
“EV-associated PD-L1 directly inhibits T cell activation and proliferation, an effect reversible by PD-1 blockade [177,178].”
Yang, S. Y., Tang, J., Yu, C., Liu, M., Lv, Z., Zhang, R., Zhang, C., Yao, C., & Yang, D. (2024) · Advanced Functional Materials · doi:10.1002/adfm.202404900 · Cited by 10
Immune checkpoints in immune response to glioma: two sides of the same coin
Musatova, O. E., Kumar, V. S., Vinogradov, K., & Rubtsov, Y. P. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1639521 · Cited by 11
“Tumor PD-L1 can be exposed on the surface of GBM-derived extracellular vesicles and delivered to the distant sites by bloodstream (15).”
Advances and challenges in clinical applications of tumor cell-derived extracellular vesicles
Li, Y., Zeng, X., Hu, X., Wen, Q., & Chen, P. (2023) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2023.113704 · Cited by 8
Prostasin regulates PD-L1 expression in human lung cancer cells
Chen, L., Chai, J. C., Liu, B., Strutt, T. M., McKinstry, K. K., & Chai, K. X. (2021) · Bioscience Reports · doi:10.1042/bsr20211370 · Cited by 7
EV PD-L1 Contributes to Immunosuppressive CD8 + T Cells in Peripheral Blood of Pediatric Wilms Tumor
Zhang, X., Liu, Z., Hou, Y., Jiao, H., Ren, J., & Wang, G. (2021) · Technology in Cancer Research & Treatment · doi:10.1177/15330338211041264 · Cited by 7
“However, recent studies demonstrated that PD-L1 can also be expressed on the surface of extracellular vesicles (EV) and EV PD-L1 (ePD-L1) levels have been associated with tumor progression in some types of adult cancer.(13-16) Tumor-derived EVs also reported can regulate the tumor-infiltrating lymphocytes(17) and exos…”
BackgroundResultInfluentialDelivering Glioblastoma a Kick—DGKα Inhibition as a Promising Therapeutic Strategy for GBM
Purow, B. W. (2022) · Cancers · doi:10.3390/cancers14051269 · Cited by 8
“Interestingly, the treatment-resistant MES GBM subtype has much higher expression of the immune checkpoints PD-L1 and TIM3 than PN GBM [33,34].”
BackgroundExosomal PD-L1 induces immunosuppressive nonclassical monocytes
Diaz, A. A. (2020) · Neuro-Oncology · doi:10.1093/neuonc/noaa100 · Cited by 7
The role of exosomal PD-L1 in NSCLC immunotherapy
Li, Z., Zhang, S.-C., Wang, Y., & Yan, Y. (2025) · Immunotherapy · doi:10.1080/1750743x.2025.2539060 · Cited by 6
Peptide-based strategies for glioblastoma therapy: From small molecular drugs to delivery vehicles
Song, N., Xiong, W., Zhu, J., Zhu, C., Gu, X., & Yu, Z. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.114023 · Cited by 7
Garcia, L. M. C., Bouchal, S. M., Bauman, M. M. J., & Parney, I. F. (2023) · Neurosurgery · doi:10.1227/neu.0000000000002393 · Cited by 6
Exosomal PDL1 Suppresses the Anticancer Activity of CD8+ T Cells in Hepatocellular Carcinoma
Hu, Q., Chen, S., Deng, R., Deng, H., Peng, M., Wang, X., Deng, S., Wang, J., Xu, B., Xu, Y., et al. (2024) · Analytical Cellular Pathology · doi:10.1155/2024/1608582 · Cited by 10
“For example, PDL1 on surface of exosomes released by glioblastoma stem cells inhibits the activation and proliferation of CD4 + and CD8 + T cells [36, 37].”
BackgroundLi, Z., Zhang, X., Qi, Y., & Wang, Z. (2025) · Molecular Immunology · doi:10.1016/j.molimm.2025.01.001 · Cited by 6
Gouhar, S. A., Elmageed, Z. Y. A., & El‐Daly, S. M. (2025) · International review of cytology · doi:10.1016/bs.ircmb.2025.01.006 · Cited by 7
Izhar, M., Kattaa, A. H., Akhavan-Sigari, A., Shaghaghian, E., Hori, Y. S., Lam, F. C., Abu-Reesh, D., Emrich, S. C., Ustrzynski, L., Tayag, A. T., et al. (2025) · Extracellular Vesicle · doi:10.1016/j.vesic.2025.100075 · Cited by 6
The Detection of Exosomal PD-L1 in Peripheral Blood
Wang, R., Yang, Y., Huang, J., & Yao, Y. (2023) · Methods in molecular biology · doi:10.1007/978-1-0716-3346-5_13 · Cited by 6
Hao, Z., Guan, W., Wei, W., Li, M., Xiao, Z., Sun, Q., Pan, Y., & Xin, W. (2025) · Journal of Neuroinflammation · doi:10.1186/s12974-025-03405-7 · Cited by 6
“In their study, PD-L1 was found on the surface of some glioblastoma-derived EVs, both PD-L1 and PD-L1 DNA were identified as cargos of glioma-derived EVs in the process of T cell inhibition [238].”
Extracellular Vesicles as a Source of Biomarkers for Cancer Diagnosis
Ovchinnikova, L. A., & Lomakin, Y. A. (2025) · Acta Naturae · doi:10.32607/actanaturae.27591 · Cited by 6
Yang, Y., Wang, S., Shi, X., Chen, X., Zhou, R., Sheng, T., Chen, X., Han, J., Xu, Y., Wu, Q., et al. (2026) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2419694123 · Cited by 5
“Of note, IFN - γ is able to upregulate the expression of PDL1 in tumor cells (38), and thus the combination of M - Ad5 with aPDL1 therapy could augment the objective response rate of synergistic therapy.”
Fu, Q.-Y., Xiong, X., Xia, H.-F., Liu, X.-C., Yu, Z., Liu, K., Zeng, J., Sun, Y., Jia, J., & Chen, G. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.216897 · Cited by 5
Extracellular RNA in oncogenesis, metastasis and drug resistance
Nelson, H., Qu, S., Franklin, J. L., Liu, Q., Pua, H. H., Vickers, K. C., Weaver, A. M., Coffey, R. J., & Patton, J. G. (2024) · RNA Biology · doi:10.1080/15476286.2024.2385607 · Cited by 5
Wu, L., Wei, D., Chen, W., Wu, C., Lu, Z., Li, S., & Liu, W. (2024) · Journal of Computer Assisted Tomography · doi:10.1097/rct.0000000000001644 · Cited by 7
Castro-Manrreza, M. E., Romano, L. E., López-García, L., Contreras, O. M., & Montesinos, J. J. (2025) · Stem Cells and Development · doi:10.1089/scd.2025.0064 · Cited by 5
The effects of tumor‐derived exosomes on T‐cell function and efficacy of cancer immunotherapy
Hao, Y., Chen, P., Zhang, X., Shao, Y., Xu, Y. Y., & Qian, W. (2021) · ImmunoMedicine · doi:10.1002/imed.1029 · Cited by 6
Chen, Z., & Yam, J. W. P. (2022) · Clinical and Translational Discovery · doi:10.1002/ctd2.111 · Cited by 7
Progress of Exosomes in Cancer Immunotherapy
Wang, Y., Wang, J., Li, H., Deng, S., & Li, Y. (2025) · Cell Biochemistry and Function · doi:10.1002/cbf.70140 · Cited by 4
“In addition to directly acting upon T cells, PD ‐ L1 ‐ bearing exosomes may also enhance immunosuppression via indirect pathways, such as inducing the production of the immunosuppressive cytokine IL ‐ 10 [95].”
Advanced extracellular vesicle immunotherapy
Zhang, J., Mu, Y., Ji, X., Jiang, X., Wang, R., Ding, X., & Wang, L. (2026) · FlexMat. · doi:10.1002/flm2.70030 · Cited by 4
Kiel, K., Małuszek, M., Piwocka, K., Godlewski, J., & Bronisz, A. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1799028 · Cited by 4
Self-citationGorgulho, J., Masood, R., Buescher, G., Giehren, F., Salié, H., David, D., Pagani, F., Kocheise, L., Schmidt, C., Waldmann, M., et al. (2026) · Gut · doi:10.1136/gutjnl-2025-337617 · Cited by 4
Self-citationHu, X., Zeng, H., Peng, Y., Deng, M., Xiang, W., Liu, B., Liu, J., Fu, Y., Hu, Z., Hou, W., et al. (2023) · Small Science · doi:10.1002/smsc.202300104 · Cited by 6
Chen, C.-H., Hsu, S.-Y., Yu, W.-J., Chiang, C., & Yu, C. (2024) · Journal of Cancer · doi:10.7150/jca.103595 · Cited by 4
“Recent studies have shown the role of EVs in TME development[12-14].”
Self-citationA game of hide-and-seek: how extracellular vesicles evade the immune system
Ghoshal, B., & Jhunjhunwala, S. (2025) · Drug Delivery and Translational Research · doi:10.1007/s13346-025-01789-w · Cited by 5
“To avoid such clearance, potentially, tumour derived EVs have ‘evolved’ means to modulate immune cell responses such that tumour growth and metastasis remain unhindered [36, 37].”
Yu, H., Shi, M., Li, X., Liang, Z., Li, K., Hu, Y., Li, S., Zhang, M., Yang, Y., Li, Y., et al. (2025) · Chinese Medical Journal · doi:10.1097/cm9.0000000000003544 · Cited by 7
“[18] The elevated expression of the two components of the PD-L1/PD-1 axis in T cells and APCs or exosomes [20] in tumors during HCC progression increases the likelihood of the engagement of this pathway.”
Schweiger, M. W., & Tannous, B. A. (2020) · Advanced Biosystems · doi:10.1002/adbi.202000035 · Cited by 4
[Research Advances of Immunotherapy of Exosome PD-L1 in Non-small Cell Lung Cancer].
Wang, N., & Song, X. (2022) · PubMed Central · doi:10.3779/j.issn.1009-3419.2022.102.33 · Cited by 6
Advances in liquid biopsy and virtual biopsy for care of patients with glioma: a narrative review
Awais, M., Rehman, A., & Bukhari, S. S. (2025) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2025.2489629 · Cited by 4
“PD-L1 (programmed death-1 ligand) expression inside EVs derived from patients with GBM was reported by Ricklefs et al. to correlate with tumor aggressiveness and serve as a potential prognostic biomarker [26].”
Targeting the molecular mechanisms of glioma stem cell resistance to chemotherapy
Fares, J., Kanojia, D., Cordero, Á., Ulasov, I. V., & Lesniak, M. S. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-821567-8.00014-2 · Cited by 6
Red blood cell distribution width in glioblastoma
Kelly, P. D., Dambrino, R. J., Guidry, B. S., Tang, A. R., Stewart, T. G., Mistry, A. M., Morone, P. J., & Chambless, L. B. (2021) · Clinical Neurology and Neurosurgery · doi:10.1016/j.clineuro.2021.107096 · Cited by 5
Methods for the Detection of Circulating Biomarkers in Cancer Patients
Mondelo‐Macía, P., Rodríguez‐Ces, A. M., Suárez‐Cunqueiro, M. M., & Muinelo‐Romay, L. (2022) · Advances in experimental medicine and biology · doi:10.1007/978-3-031-04039-9_21 · Cited by 5
Chen, X., Chen, H., Lin, R., Li, Y., Guo, Y., Chen, Q., Zhang, Y., Cai, G., Hu, M., & Chen, G. (2022) · Journal of Clinical Pathology · doi:10.1136/jcp-2021-207795 · Cited by 4
Hellmold, D., Kubelt, C., Daunke, T., Beckinger, S., Janßen, O., Hauck, M., Schütt, F., Adelung, R., Lucius, R., Haag, J., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24109075 · Cited by 4
“[84] presented that the programmed cell death 1 ligand was present in EVs, which could systemically suppress an anti-tumor immunity by inhibiting T cell activation.”
BackgroundGool, S. V., de Vliet, P. V., Kampers, L. F. C., Kosmal, J., Sprenger, T., Reich, E. D., Schirrmacher, V., & Stuecker, W. (2023) · Methods in cell biology · doi:10.1016/bs.mcb.2023.06.001 · Cited by 5
Scoparone attenuates PD-L1 expression in human breast cancer cells by MKP-3 upregulation
Kim, S.-W., Kim, C. W., & Kim, H. S. (2024) · Animal Cells and Systems · doi:10.1080/19768354.2024.2315950 · Cited by 4
“PD-L1 is one of the most important molecular pathways used by tumor cells to evade the immune checkpoints of T cells (Ricklefs et al. 2018; Kumagai et al. 2020).”
BackgroundFerreira, A. L., Menezes, A., Sandim, V., Monteiro, R. Q., Nogueira, F. C. S., Evaristo, J. A. M., Pereira, D. D. A., & Carneiro, K. (2024) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2024.150847 · Cited by 3
Gerson, G., Nogueira, G. N., Saldanha, I. M. R., Farias, A. G. P., MATEUS, . M., Neto, O. M. V., & Teixeira, M. J. (2024) · Journal of Surgical Oncology · doi:10.1002/jso.27986 · Cited by 3
“Prognostic stratification based on the combined mutational status of TERTp ‐ mut and IDH revealed four distinct groups, highlighting the importance of individual mutations and their interactions in tumorigenesis [20].”
Extracellular vesicles as brain tumor biomarkers
Gilazieva, Z., Moldavskii, D., LUZINA, E., KADYROVA, A., SHAIMARDANOVA, A., Solovyeva, V. V., Rizvanov, A. A., & Issa, S. S. (2024) · Biocell · doi:10.32604/biocell.2024.058490 · Cited by 3
Yao, P., Ju, H., Song, A., Wang, Y., Xin, G., Wang, G., Ma, J., & Guo, M. (2025) · International Immunopharmacology · doi:10.1016/j.intimp.2025.114629 · Cited by 3
Nanocarrier Strategies in Glioblastoma: Overcoming Barriers to Effective Brain Tumor Therapy
Khan, S., Haider, M. F., & Rab, S. O. (2025) · AAPS PharmSciTech · doi:10.1208/s12249-025-03283-5 · Cited by 3
“However, glioblastoma cells often express high levels of PD-L1 (Programmed Death Ligand 1) on their surface [21].”
Advancing glioblastoma immunotherapy: Molecular pathways and innovative therapeutic strategies
Tang, M., Xu, P., & Zhang, X. (2025) · Pathology - Research and Practice · doi:10.1016/j.prp.2025.156326 · Cited by 6
Levite, M., Ilouz, N., Galun, E., & Shoshan, Y. (2026) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-025-04226-6 · Cited by 3
Collagen-Bearing Exosomes from Breast Cancer–Associated Fibroblasts Promote T-cell Dysfunction
Jana, S., Lawton, M. L., Lei, P., Hui, H., Emili, A., & Jones, D. (2026) · Cancer Research Communications · doi:10.1158/2767-9764.crc-25-0259 · Cited by 5
Biological Cargo: Exosomes and their Role in Cancer Progression and Metastasis
Tripathi, S., Sharma, Y., & Kumar, D. (2024) · Current Topics in Medicinal Chemistry · doi:10.2174/0115680266304636240626055711 · Cited by 4
The roles of extracellular vesicles in gliomas: Challenge or opportunity?
Huang, L., Zhan, J., Li, Y., Huang, K., Zhu, X., & Li, J. (2024) · Life Sciences · doi:10.1016/j.lfs.2024.123150 · Cited by 3
Astrocytes in Glioblastoma Therapy: A Novel Approach to Targeting Tumor Microenvironment
Jayasinghe, R., & Danushka, P. G. N. (2025) · IntechOpen eBooks · doi:10.5772/intechopen.1008927 · Cited by 3
Metadata
- Authors
- Ricklefs, F. L., Alayo, Q., Krenzlin, H., Mahmoud, A. B., Speranza, M. C., Nakashima, H., Hayes, J. L., Lee, K., Balaj, L., Passaro, C., Rooj, A. K., Krasemann, S., Carter, B. S., Chen, C. C., Steed, T., Treiber, J., Rodig, S., Yang, K., Nakano, I., Lee, H., Weissleder, R., Breakefield, X. O., Godlewski, J., Westphal, M., Lamszus, K., Freeman, G. J., Bronisz, A., Lawler, S. E., & Chiocca, E. A.
- Affiliations
- Brigham and Women's Hospital (US)
- University of California, Berkeley (US)
- Massachusetts General Hospital (US)
- University Medical Center Hamburg-Eppendorf (DE)
- University of California San Diego (US)
- Comprehensive Cancer Center, University of Birmingham, Birmingham, AL 35294, USA.
- Harvard University (US)
- Corresponding author
- Lawler, Sean E.
- Chiocca, E. Antonio
- ORCID
- Ricklefs, Franz L.
- Alayo, Quazim
- Krenzlin, Harald
- Mahmoud, Ahmad B.
- Speranza, Maria C.
- Nakashima, Hiroshi
- Hayes, Josie L.
- Lee, Kyungheon
- Balaj, Leonora
- Passaro, Carmela
- Rooj, Arun K.
- Krasemann, Susanne
- Carter, Bob S.
- Chen, Clark C.
- Steed, Tyler
- Treiber, Jeffrey
- Rodig, Scott
- Yang, Katherine
- Nakano, Ichiro
- Lee, Hakho
- Weissleder, Ralph
- Breakefield, Xandra O.
- Godlewski, Jakub
- Westphal, Manfred
- Lamszus, Katrin
- Freeman, Gordon J.
- Bronisz, Agnieszka
- Lawler, Sean E.
- Chiocca, E. Antonio
- Venue
- Science Advances
- Published
- 2018-03-02
- Volume
- 4
- Issue
- 3
- Pages
- eaar2766-eaar2766
- ISSN
- 2375-2548 (ISSN-L)
- PMC
- PMC5842038
- OpenAlex
- W2793992337
- Cited by
- 610
- References
- 42
- Citations by year
- 2026: 48 · 2025: 68 · 2024: 76 · 2023: 76 · 2022: 85 · 2021: 111 · 2020: 75 · 2019: 56 · 2018: 15
- FWCI
- 22.86
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- Science Advances (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
- Funders
- National Institutes of Health (CA176203-01A1)
- National Cancer Institute (P01 CA69246)
- Deutsche Forschungsgemeinschaft (RI 2616/1-1, RI 2616/2-1)
- National Institute of Health (NCI P01 CA69246)
- American-Italian Cancer Foundation Post-doctoral Research Fellowship
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Extracellular vesicles in disease
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
- Keywords
- glioblastoma, PD-L1, extracellular vesicles, immune evasion, antitumor immunity, tumor microenvironment, biomarkers
- MeSH terms
- Extracellular Vesicles, Antigens, Neoplasm, Brain Neoplasms, Glioblastoma, Humans, Interferon-gamma, Lymphocyte Activation, Receptors, Antigen, T-Cell, T-Lymphocytes, Neoplastic Stem Cells, Up-Regulation, Gene Expression Regulation, Neoplastic, Cell Line, Tumor, Immune Evasion, B7-H1 Antigen
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.